Mersana Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Mersana Therapeutics's estimated annual revenue is currently $43k per year.
- Mersana Therapeutics received $33.0M in venture funding in June 2016.
- Mersana Therapeutics's estimated revenue per employee is $193
- Mersana Therapeutics's total funding is $480.6M.
- Mersana Therapeutics's current valuation is $451.6M. (January 2022}
- Mersana Therapeutics has 223 Employees.
- Mersana Therapeutics grew their employee count by 42% last year.
Mersana Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Mersana Therapeutics?
Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug's chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana's ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today's cancer treatments.keywords:N/A
Number of Employees
Employee Growth %
Mersana Therapeutics News
CAMBRIDGE, Mass., June 16, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Fleximer® technology, today announced the completion of a $33 million Series C fina ...
Mersana Therapeutics, Inc., a Cambridge, MA-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs), completed a $33m Series C financing. The round was led by new investor Wellington Management Company with participation from new investors ...
CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced th ...
Mersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and ...
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (MRSN) a clinical-stage biopharmaceutical company ...
Mersana Therapeutics Inc (NASDAQ:MRSN) has been given a consensus rating of “Buy” by the eight research firms that are presently covering ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Mersana Therapeutics Funding
|2012-08-01||$27.0M||A-1||New Enterprise Associates||Article|
|2015-03-03||$35.0M||B-1||New Enterprise Associates||Article|
|2016-06-17||$33.0M||C||Wellington Management Company||Article|